Drug Discovery Today - Pharmacology/ Therapeutics

Latest News

Cellzome in €500m GlaxoSmithKline deal
Cellzome announces second major strategic drug discovery alliance with GlaxoSmithKline in inflammatory disease.
Cambridge, UK to host BioFine Europe 2010
BioFine Europe 2010 will take place from 30–31 March and features The Peptide Conference 2010, the Synthetic Biology in Pharma conference and the BioFine Europe Exhibition.
Alizé Pharma signs research collaboration and license option agreement with Lilly
Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of type II diabetes.
Rexahn Pharmaceuticals granted European patent for anti-cancer compound, RX-3117
Rexahn Pharmaceuticals announces that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.
Clinical candidate from PKB/AKT collaboration with Astex selected by AstraZeneca
Astex Therapeutics announced recently that AstraZeneca has selected a clinical candidate from the PKB inhibitor collaborative programme.

Podcasts

Evotec strengthens and expands its Alliance Business
Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
The Ubiquitin Story
In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
Download the Califf, Behrman and Kramer podcast as an mp3 file
Dr Brent Vose outlines AstraZeneca's oncology pipeline.
Download the Dr. Brent Vose podcast as an mp3 file

Webinars

The renaissance of clinical biochemistry: Diagnostic biomarker discovery by targeted metabolomics
Metabolomics, i.e. the systematic identification and quantitation of marker metabolites in a given compartment, cell, tissue or body fluid, is increasingly recognized as the most relevant approach to depicting the functional end-points of physiological and pathophysiological processes. Yet, a reliable and standardized technology platform rendering metabolomics applicable to routine diagnostics has not been in place so far.
Aequorin Bioluminescence Assays – a paradigm shift?
Metabolomics, a Novel Tool for Understanding the Early-Stage Mechanistic Underpinnings of Drug Action and Safety.
In association with Matabolon. This presentation demonstrated the utility of metabolomics in drug safety research through a case study done in collaboration with Teva Pharmaceutical Industries Ltd.

Downloads

Aptocine-Mediated Systemic Immune Tumor Destruction: An Emerging Intratumoral Whole Cell Autologous Vaccine
This is a white paper addressing the immunotherapeutic potential of the development product Aptocine and puts it in the context of current treatments and other 'cancer vaccines' in development.

25 Hottest Articles

The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? • Review article
Drug Discovery Today, Volume 14, Issue 21-22, November 2009, Pages 1011-1020 | Ritchie, T.J.; Macdonald, S.J.F.
The road ahead for large pharma: long-term science and innovation • Editorial
Drug Discovery Today, Volume 14, Issue 9-10, May 2009, Pages 439-441 | Lundberg, J.M.; Reilly, C.
The growing impact of click chemistry on drug discovery • Review article
Drug Discovery Today, Volume 8, Issue 24, December 2003, Pages 1128-1137 | Kolb, H.C.; Sharpless, K.B.
Homology modeling in drug discovery: current trends and applications • Review article
Drug Discovery Today, Volume 14, Issue 13-14, July 2009, Pages 676-683 | Cavasotto, C.N.; Phatak, S.S.
Text-based knowledge discovery: search and mining of life-sciences documents • Review article
Drug Discovery Today, Volume 7, Issue 11, May 2002, Pages S89-S98 | Mack, R.; Hehenberger, M.

Latest News

Podcasts

Webinars

Downloads

25 Hottest Articles

Members' Login

Not a member?